Mark J. Ratain to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Mark J. Ratain has written about Protein-Tyrosine Kinases.
Connection Strength
1.148
-
Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4.
Score: 0.374
-
Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006 Nov 07; 145(9):702-3.
Score: 0.245
-
EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
Score: 0.215
-
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol. 2011 Jun; 71(6):917-20.
Score: 0.084
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.084
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.081
-
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95.
Score: 0.066